2012/01/31 11:09 - Mesoblast Limited (ASX:MSB) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its proprietary adult stem cells for the treatment of Type 2 diabetes.
2011/12/16 12:18 - Asian Activities Report for December 16, 2011 includes: Asahi Glass Co., Ltd. (TYO:5201) will establish a new cathode materials production and sales site in China for lithium-ion batteries used in mobile devices and electronic vehicles; FUJIFILM Holdings Corporation (TYO:4901) has signed a definitive agreement to acquire all outstanding shares of SonoSite, Inc. (NASDAQ:SONO) for approximately US$995 million; Kobe Steel, Ltd. (TYO:5406) plans to increase the production capacity of its Chinese subsidiary which makes aluminum forgings for automotive suspensions; Eisai Co., Ltd. (TYO:4523) has received approval from Health Canada for Halaven(TM), a novel anticancer agent for the treatment of metastatic breast cancer.
2011/11/24 11:24 - Mesoblast Limited (ASX:MSB) Chief Executive, Professor Silviu Itescu, today provided shareholders at Mesoblast's Annual General Meeting with an overview of the company's corporate strategy and major highlights of recent achievements.
2011/11/24 09:48 - Mesoblast Limited (ASX:MSB) Chairman's Address and CEO's Presentation to Shareholders
2011/11/22 10:08 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell (MPC) technology in patients with Type 2 Diabetes. Based on the positive outcome of the FDA meeting held on November 18, Mesoblast will file an Investigational New Drug (IND) submission within the next 30-60 days to seek clearance for patient recruitment.
2011/11/15 08:25 - Regenerative medicine company Mesoblast Limited (ASX:MSB) today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor(TM) after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months. The Phase 2 trial results in 60 patients were presented at the American Heart Association annual meeting in Orlando, Florida, by the trial's independent principal investigator Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute in Houston.
2011/11/10 08:27 - Regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by significant reductions in circulating inflammatory markers to levels associated with protection against heart attacks and death in patients with Type 2 diabetes. Results of the study were presented at the Credit Suisse Healthcare conference in Phoenix, Arizona.
2011/11/01 12:00 - Asian Activities Report for November 1, 2011 includes: Montezuma Mining Company Ltd (ASX:MZM) reports outstanding copper results from a recently completed 19-hole drilling programme at the Company's 100% owned Butcherbird Copper Project in Western Australia; Hannans Reward Ltd (ASX:HNR) provides an update on its drilling program currently underway at the Jigalong Project; Biomedical company, Tissue Therapies Limited (ASX:TIS) says today that the VitroGro(R) synthetic protein has been classified as a biologic product by the US Food and Drug Administration; Navigator Resources Limited (ASX:NAV) has achieved the production milestone of 100,000 ounces of gold poured since it commenced operation at the Company's Bronzewing Gold Project, located 960km northeast of Perth.
2011/10/31 10:36 - Agenix Limited (ASX:AGX) is pleased to provide Chairman's Address to shareholders at 2011 Annual General Meeting.
2011/10/27 12:00 - Asian Activities Report for October 27, 2011 includes: C @ Limited (ASX:CEO) has signed an agreement to acquire eight highly prospective Mongolian coal licences for US$7.8 millions; African Iron Limited (ASX:AKI) announces a 267% increase in the JORC hematite mineral resource to 121 million tonnes at its 92% owned Mayoko Iron Ore Project in Congo; ENK Plc (ASX:ENK) announces the first nickel production from its pilot plant located 250 km north of Manila in the Philippines; Solagran Limited (ASX:SLA) recently visited an Asian country where a poultry trial was conducted in collaboration with a government body in the field of poultry production and disease management.
2011/10/24 09:48 - Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes - neovascular ("wet") Age-related Macular Degeneration (AMD). Wet AMD causes sudden and severe central vision loss and accounts for approximately 90 percent of all blindness in the elderly. Mesoblast is developing a stem cell therapeutic product for treating various vascular diseases of the eye, including wet AMD and diabetic macular edema (DME).
2011/10/20 10:21 - Mesoblast Limited (ASX:MSB) and its strategic alliance partner Cephalon Inc. were today awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction(TM) Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences sector.
2011/10/18 13:03 - Asian Activities Report for October 18, 2011 includes: Algae. Tec Limited (ASX:AEB) has received regulatory approvals for the development of an algae demonstration plant in the south of Sydney; Helicon Group Limited (ASX:HCG) today announces the execution of a definitive agreement to acquire Aspen Medisys; Alkane Resources Limited (ASX:ALK) has signed an agreement with the NSW Government to receive financial assistance for the infrastructure development of the Tomingley Gold Project in the Central West of NSW; Transerv Energy Limited (ASX:TSV) has completed the initial 10-day test of the Upper Zone at the Warro-4 onshore well in Western Australia; Augur Resources Limited (ASX:AUK) reports extensive gold and copper results from the Randu Kuning prospect, Wonogiri project in Central Java.
2011/10/17 12:00 - Asian Activities Report for October 17, 2011 includes: International Coal Limited (ASX:ICX) has expanded the drilling programme at its wholly owned South Blackall Project in Queensland; Avanco Resources Limited (ASX:AVB) reported excellent results from the Rio Verde Copper Project in Brazil; Cardia Bioplastics Limited (ASX:CNN) has received BioNexus Status in Malaysia; Mantle Mining Corporation Limited (ASX:MNM) has completed the first 4 holes of a 15 hole drill program at the Company's 100% owned Bacchus Marsh coal project in Victoria; Vocus Communications (ASX:VOC), a Seven Group Holdings (ASX:SVW) company, has secured a multi-year deal to provide IP Transit and Data Centre services to leading 4G wireless provider vividwireless.
2011/10/13 08:26 - Agenix Limited (ASX:AGX) today confirmed it had signed two new agreements with its strategic partners in China covering the commercialisation of new drug candidates, the sharing of resources, expertise and completion of pre-clinical toxicology tests for its new hepatitis B drug in China.
2011/10/10 12:00 - Asian Activities Report for October 10, 2011 includes: Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director; Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect; Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100; Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment.
2011/09/30 14:32 - Agenix Limited (ASX:AGX) confirmed its promising new hepatitis B drug, AGX-1009, shared the same active compound as Gilead's blockbuster drug, Viread, which is widely used to treat HIV and hepatitis throughout Asia.
2011/09/30 12:00 - Asian Activities Report for September 30, 2011 includes: Neon Energy Limited (ASX:NEN) says today that the recently drilled Lombardi 19-27H development well in the North San Ardo oil field, onshore California, has been brought onstream; India Resources Limited (ASX:IRL) has signed a A$249M coal operations contract with Prism Cement Limited (BOM:500338) to develop and operate the first phase of Prism's Sial Ghoghri coal mine; Guildford Coal Limited (ASX:GUF) has upgraded its Exploration Targets at its Mongolian coal projects to 30Mt to 1.380Bt; Tissue Therapies Limited (ASX:TIS) will start the sales of VitroGro(R) for the treatment of chronic wounds in the UK and Europe during the second quarter of 2012; Biotron Limited (ASX:BIT) has commenced a human trial of its lead HIV drug candidate, BIT225; Circadian Technologies Limited (ASX:CIR) has submitted an investigational new drug application to the FDA to initiate clinical studies of VGX-100.
2011/09/27 08:27 - Global regenerative medicine company Mesoblast Limited (ASX:MSB) and Lonza Group (VTX:LONN), a world leader in biologic manufacturing, today announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast's off-the-shelf (allogeneic) adult stem cell products.
2011/09/05 08:36 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor(TM) is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks.
2011/08/24 10:00 - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided its full year financial results. The company stated that it had substantial funds of A$263.2 million at 30 June 2011. Mesoblast recorded revenue and other income of A$120.9 million and a profit before tax of A$92.2 million.
2011/08/22 08:32 - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the first minimally-invasive lumbar disc procedure had been successfully performed in the Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell product for the treatment of low back pain and degenerative disc disease. The outpatient procedure lasted less than 20 minutes, with the patient fully awake and under light sedation. The patient was shortly discharged and there were no complications.
2011/08/15 09:40 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its heart failure clinical trial has been chosen by the American Heart Association to be featured at its 2011 annual conference in Orlando, Florida, in the "Clinical Science: Special Reports" session on November 14. More than 17,000 international cardiovascular specialists are expected to attend the conference.
2011/07/07 09:23 - Global regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancers. FDA clearance was obtained within the 30-day minimum time period after Mesoblast filed its Phase 3 Investigational New Drug submission.
2011/06/29 09:22 - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration to begin a Phase 2 clinical trial of its proprietary adult Mesenchymal Precursor Cell (MPC) product for the treatment of degenerative disc disease.
2011/06/14 12:26 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), was featured today at the 8th Nomura Asia Equity Forum being held in Singapore. Mesoblast was the only Australian company to present at the respected Asian investor forum.
2011/06/09 09:39 - Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare Conference in California today.
2011/06/06 10:19 - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its Chief Executive, Silviu Itescu, will present at the Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference in the United States. Mesoblast joins Resmed and Ramsay Healthcare as the only Australian companies participating in the global investor forum.
2011/05/24 09:40 - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
2011/05/02 12:00 - Asian Activities Report for May 2, 2011 includes: East Energy Resources Limited (ASX:EER) announced a maiden JORC Indicated Resource of 469 million tonnes of thermal coal at its Blackall Coal Project in Central Queensland; Oilex Limited (ASX:OEX) advises that the La Rocca-1 well on the WA-388-P permit offshore Western Australia was spudded on 30 April 2011; PT ANTAM (Persero) Tbk (ASX:ATM) reported strong corporate results for the first quarter of 2011; Bioniche Life Sciences Inc. (TSE:BNC) (ASX:BNC) opened its new Animal Health and Food Safety Vaccine Manufacturing Centre in Canada.
2011/04/27 09:58 - Sino Gas & Energy Holdings Limited (ASX:SEH), an Australian company developing unconventional gas assets within the Ordos Basin, Shanxi Province China, is pleased to advise that it has signed an agreement to raise up to A$29.4 million in new funds from SpringTree Special Opportunities Fund, LP, a New York-based institutional investor, over the next two years.
2011/04/18 09:41 - Standard and Poor's Indices has announced that regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) will be included in the S&P/ASX 200 Index, effective after the close of business on Wednesday 27 April, 2011.
2011/04/11 08:52 - Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to announce that it is undertaking a fully underwritten Renounceable Rights Issue to raise approximately $8 million, following an agreement reached with La Jolla Cove Investors Inc to terminate their convertible note funding arrangement with Benitec.
2011/04/07 09:19 - Mesoblast Limited (ASX:MSB) (PINK:MBLTY) wishes to inform the market that the Board of its strategic partner Cephalon Inc. (NASDAQ:CEPH) has rejected the unsolicited proposal from Valeant Pharmaceuticals International Inc (NYSE:VRX) to acquire its issued share capital or certain assets.
2011/03/31 17:50 - Mesoblast Limited (ASX:MSB) (PINK:MBLTY), has received a number of enquiries from shareholders and analysts regarding yesterday's announcement by Mesoblast's strategic partner Cephalon Inc. (NASDAQ:CEPH) that it had received an unsolicited proposal from Valeant Pharmaceuticals International Inc (TSE:VRX) to acquire Cephalon's issued share capital or certain assets. Mesoblast continues to maintain a close dialogue with Cephalon.
2011/03/29 14:24 - Benitec Limited (ASX:BLT) (PINK:BNIKF) today welcomed the publication of research by scientists at the University of Queensland who demonstrated the value of Benitec's gene silencing platform technology to provide effective human therapeutics for cancer. Their results were published this month in the prestigious international scientific journal Cancer Gene Therapy.
2011/03/22 13:56 - Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, today announced further positive progress in its fundamental Graham family patent applications exclusively licensed from CSIRO worldwide for human therapeutics. These patents cover silencing of genes using DNA-directed RNA interference (ddRNAi). Progress on these patent applications further strengthens Benitec's position with regards to both its revenue opportunities from licensing of ddRNAi technology for research use and in the commercialization potential of its ddRNAi-based therapeutics, being developed both in house and for the treatment of chronic and life threatening medical conditions, such as infectious diseases and cancer.
2011/03/21 10:59 - Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in RNA-based gene silencing for human therapeutics, is pleased to acknowledge that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec's DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.
2011/03/17 09:43 - Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that Chief Executive Officer Professor Silviu Itescu has been named BioSpectrum Asia Pacific Person of the Year 2011. BioSpectrum Asia is the leading Asian life sciences publication.
2011/02/28 17:17 - Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today reported its half year results for the period ended 31 December 2010. At the reporting date, Mesoblast recorded funds of $140.6 million but has since nearly doubled its cash reserves to $279 million after an equity purchase by global biopharmaceutical company Cephalon Inc. (NASDAQ:CEPH) that brings its total Mesoblast holding to 19.99%.
Biotech